General form of registration statement for all companies including face-amount certificate companies

Accounts Payable and Accrued Expenses (Tables)

v3.24.4
Accounts Payable and Accrued Expenses (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Accounts Payable and Accrued Expenses    
Schedule of Accounts Payable and Accrued Expenses

​

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

($ in thousands)

​

2024

    

2023

​

Accounts payable

​

$

8,759

​

$

6,322

​

Accrued research and development

​

​

561

​

​

4,118

​

Accrued compensation

​

​

984

​

​

2,838

​

Other (1)

​

​

1,757

​

​

739

​

Total accounts payable and accrued expenses

​

$

12,061

​

$

14,017

​

(1) Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.

At December 31, 2023 and 2022, accounts payable and accrued expenses consisted of the following:

​

​

​

​

​

​

​

​

​

December 31,

($ in thousands)

​

2023

    

2022

Accounts payable

​

$

6,322

​

$

6,833

Accrued research and development

​

​

4,118

​

​

2,782

Accrued compensation

​

​

2,838

​

​

3,468

Other

​

​

739

​

​

648

Total accounts payable and accrued expenses

​

$

14,017

​

$

13,731